Signaturefd LLC Reduces Stock Holdings in DaVita Inc. (NYSE:DVA)

Signaturefd LLC lessened its stake in shares of DaVita Inc. (NYSE:DVA) by 39.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 457 shares of the company’s stock after selling 294 shares during the quarter. Signaturefd LLC’s holdings in DaVita were worth $63,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DVA. 8 Knots Management LLC purchased a new stake in DaVita in the fourth quarter valued at $89,504,000. Doma Perpetual Capital Management LLC purchased a new stake in shares of DaVita in the 4th quarter valued at about $53,076,000. Norges Bank acquired a new stake in shares of DaVita in the 4th quarter valued at about $36,626,000. Allianz Asset Management GmbH grew its stake in DaVita by 63.9% during the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after buying an additional 213,992 shares during the last quarter. Finally, Pinebridge Investments L.P. grew its stake in DaVita by 148.8% during the 4th quarter. Pinebridge Investments L.P. now owns 268,601 shares of the company’s stock worth $28,139,000 after buying an additional 160,630 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. UBS Group increased their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Truist Financial increased their target price on shares of DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Tuesday, August 20th. Finally, TD Cowen boosted their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $157.00.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the sale, the chief executive officer now owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the transaction, the chief executive officer now owns 905,659 shares in the company, valued at approximately $141,219,407.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The disclosure for this sale can be found here. Insiders have sold 113,601 shares of company stock valued at $17,525,449 over the last quarter. Company insiders own 2.00% of the company’s stock.

DaVita Stock Down 0.4 %

Shares of NYSE:DVA opened at $151.37 on Thursday. The company has a market cap of $12.70 billion, a price-to-earnings ratio of 17.20, a PEG ratio of 0.80 and a beta of 0.86. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $156.44. The firm’s 50-day simple moving average is $143.01 and its 200-day simple moving average is $138.44. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.08 EPS. As a group, equities research analysts predict that DaVita Inc. will post 9.99 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.